Role of Blood P-Tau Isoforms (181, 217, 231) in Predicting Conversion from MCI to Dementia Due to Alzheimer’s Disease: A Review and Meta-Analysis
Authors:
- Gemma LombardiGemma Lombardi
- Silvia PancaniSilvia Pancani
- Riccardo MancaRiccardo Manca
- Micaela MitoloMicaela Mitolo
- Simone BaiardiSimone Baiardi
- Federico MassaFederico Massa
- Luigi CoppolaLuigi Coppola
- Monica FranzeseMonica Franzese
- Emanuele NicolaiEmanuele Nicolai
- Franca Rosa GueriniFranca Rosa Guerini
- Roberta MancusoRoberta Mancuso
- Cristina AgliardiCristina Agliardi
Open Access
- 30 November 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 12916
Abstract
Blood-based biomarkers are minimally invasive tools to detect the pathological changes of Alzheimer’s Disease (AD). This meta-analysis aims to investigate the use of blood-derived p-tau isoforms (181, 217, 231) to predict conversion from mild cognitive impairment (MCI) to AD dementia (ADD). Studies involving MCI patients with data on blood p-tau isoforms at baseline and clinical diagnosis at follow-up (≥1 year) were included. Twelve studies on p-tau 181 (4340 MCI, conversion rate 20.6%), four on p-tau 217 (913 MCI, conversion rate 33.4%), and one on p-tau 231 (135 MCI, conversion rate 33%) were included. For p-tau 181, the pooled area under the receiver operating characteristic curve (AUC) was 0.73 (95% CI = 0.68–0.78), and for p-tau 217 was 0.85 (95% CI = 0.75–0.91). Plasma levels of p-tau 181 had good discriminatory power to identify MCI patients who will convert to ADD. Although only four studies on p-tau 217 have been included in the meta-analysis, in the last year the predictive power of p-tau 217 is emerging as superior to that of other isoforms. However, given the high heterogeneity detected in the p-tau 217 studies included in this meta-analysis, additional supportive evidence is needed. Insufficient results were available for p-tau 231. These findings support the prognostic utility of p-tau 181 and p-tau 217 measured in blood to predict progression to ADD in MCI and encourage its future implementation in clinical practice.Keywords
Funding Information
- #NEXTGENERATIONEU (NGEU) (PE0000006, DN. 1553 11.10.2022)
- Ministry of University and Research (MUR) (PE0000006, DN. 1553 11.10.2022)
- National Recovery and Resilience Plan (NRRP) (PE0000006, DN. 1553 11.10.2022)
- nervous system in health and disease (PE0000006, DN. 1553 11.10.2022)
- Italian Ministry of Health with the “Ricerca Corrente 2023” program (PE0000006, DN. 1553 11.10.2022)
This publication has 87 references indexed in Scilit:
- Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary CareJAMA, 2024
- Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive ImpairmentJAMA Neurology, 2024
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease PathologyJAMA Neurology, 2024
- Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission TomographyJAMA Neurology, 2023
- Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tauAlzheimer's & Dementia, 2021
- Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer DiseaseJAMA Neurology, 2021
- The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's diseaseAlzheimer's & Dementia, 2021
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative DisordersJAMA, 2020
- 18F PET with florbetapir for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Cochrane Database of Systematic Reviews, 2017
- Mild Cognitive ImpairmentArchives of Neurology, 1999